Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: the AvaALL randomized clinical trial.
Gridelli, C de Castro Carpeno, J Dingemans, A Griesinger, F Grossi, F Langer, C Ohe, Y Syrigos, K Thatcher, Nick Das-Gupta, A
Gridelli, C
de Castro Carpeno, J
Dingemans, A
Griesinger, F
Grossi, F
Langer, C
Ohe, Y
Syrigos, K
Thatcher, Nick
Das-Gupta, A
Citations
Altmetric:
Abstract
Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond progression in non-small cell lung cancer (NSCLC).
Description
Date
2018-08-30
Publisher
Collections
Keywords
Type
Article
Citation
Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: the AvaALL randomized clinical trial. 2018, JAMA Oncol